The current managing partner of 5AM Ventures, Scott Rocklage can boast a career filled with innovation and excellence.
Dr. Rocklage received his PhD in chemistry from the prestigious Massachusetts Institute of Technology and then enjoyed over thirty years in healthcare management. Over the course of his career, Scott Rocklage has been the inventor of or co-inventor of 30 US Patents and has contributed to over 100 peer reviewed articles.
Scott Rocklage’s leadership was crucial in attaining FDA approval for three new drugs (Omniscan™, Teslascan® and Cubicin®). He has worked as Chairman of the Board, CEO and President at such groundbreaking companies as Rennovia, Kinestral, Cidara, Nycomed Salutar, and Catalytica.
Since 2003 Dr. Rocklage has spearheaded 5AM Ventures goal to provide capital to healthcare companies seeking to find new ways to diagnose and treat a variety of conditions. His experience entering six different drugs into clinical trials has helped him understand how to best oversee and invest 5AM Venture’s over $1 Billion portfolio of clients.
His concurrent participation with WaveRx, Pulmatrix and Variation speak to Dr. Rucklage’s ongoing dedication to staying at the forefront of medical research. His collaboration on the Board of Associates at the Whitehead Institute also attests to his superior ability to collaborate effectively with his peers in developing exciting new solutions to many issues experienced in the medical community and learn more about Scott.
Based in Boston, Massachusetts, Scott Rocklage attests the ability to manage time and prioritize effectively is one of his main keys to success. He stated in a recent interview with Ideamensch that the ability to execute “measured risk taking” and choose the right people in the right part of the organization are both crucial to receiving a positive outcome and Scott’s lacrosse camp.
In looking to the future in life science, Dr. Rocklage is excited at the possibilities of further development in targeting specific gene mutations or genotypes to combat cancer in new, more effective ways and resume him.